Opinion
Video
Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.
Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Top 5 Most-Read Articles on Rare Blood Disorders in 2024
Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa
Further Refining the Myasthenia Gravis Continuum
ICYMI: Highlights From CHEST 2024